NASDAQ$SGHT

Sight Sciences Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Reported financial results for the third quarter ended September 30, 2022.

Sight Sciences reported a 43% increase in revenue compared to the third quarter of 2021, with Surgical Glaucoma revenue increasing by 37% and Dry Eye revenue increasing by 145%. The company achieved a gross margin of 84%.

  • Total revenue of $18.7 million, an increase of 43% compared to the prior year period.
  • Gross margin of 84%.
  • Increased the number of facilities ordering the OMNI® Surgical System to 913.
  • Launched the SION™ Surgical Instrument.

Headline financials

Total Revenue

$18.7M

Previous: $13.1M+42.6%
EPS (adj)

-$0.46

Previous: -$0.43-7.0%
Total Gross Margin

84.0%

Previous: 84.0%+0.0%
Operating Expenses

$37.6M

Previous: $25.1M+49.8%
Capital Expenditures

-$841K

Previous: -$656K-28.2%
Free Cash Flow

-$23.1M

Previous: -$17.8M-29.4%
Net Income

-$22.2M

Previous: -$17.2M-29.5%
Operating Income

-$21.8M

Previous: -$14M-55.7%
Gross Profit

$15.7M

Previous: $11M+42.7%
Cash & Equivalents

$200M

Previous: $271M-26.4%
Total Assets

$225M

Previous: $291M-22.6%
Stock-Based Comp

$3.22M

Previous: $1.9M+69.7%

Revenue & EPS history

Sight Sciences · Revenue · Quarterly

$18.7M

Q3 2022+42.6%vs Q3 2021
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Sight Sciences · $18.7M total across 2 segments · Q3 2022

  • Interventional Glaucoma
    $17.1M+37.9%
  • Interventional Dry Eye
    $1.6M+128.6%

Forward guidance

Sight Sciences now projects revenue for the full year 2022 to range from $70 million to $72 million, which represents growth of approximately 43% to 47% compared to 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.0%

Avg return

30 days after

53%

10 / 19 earnings

Positive

+60.9%

Q3 2022

Best reaction

-26.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.7%+22.6%+2.5%
Q4 2025-26.9%-25.9%-34.9%
Q3 2025+16.0%+54.4%+61.0%
Q1 2025+1.3%+8.3%+38.6%
Q4 2024+2.9%+15.3%-5.0%
Q3 2024-17.1%-17.1%-24.1%
Q2 2024-18.9%-29.4%-13.0%
Q1 2024+6.6%+1.1%+17.4%
Q4 2023+6.8%-4.4%+21.4%
Q3 2023+19.8%+2.0%+54.1%
Q2 2023+11.0%+4.1%-16.0%
Q1 2023-0.4%+0.6%-25.1%
Q4 2022+4.9%-2.3%-5.8%
Q3 2022+60.9%+50.4%+72.9%
Q2 2022-3.9%-16.1%-26.2%
Q1 2022+11.2%+23.9%+59.2%
Q4 2021-10.1%-6.1%-45.5%
Q3 2021-2.4%-5.8%-20.6%
Q2 2021-4.7%+0.1%-15.9%
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro